US
Updated
Reviewed by Chandani Patel
US Joint Health Supplements Market Industry Trends and Forecast to 2034: Segmented by (Ingredient, Form, Distribution Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $4.86 Bn.
Canada at 6.4% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$2.24 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $4.66 Bn | — | — |
| 2025 (base) | $4.86 Bn | +$200.5 Mn | — |
| 2026 (forecast) | $5.07 Bn | +$209.2 Mn | +4.3% |
| 2027 (forecast) | $5.29 Bn | +$218.2 Mn | +8.8% |
| 2028 (forecast) | $5.52 Bn | +$227.5 Mn | +13.5% |
| 2029 (forecast) | $5.76 Bn | +$237.3 Mn | +18.3% |
| 2030 (forecast) | $6.00 Bn | +$247.5 Mn | +23.4% |
| 2031 (forecast) | $6.26 Bn | +$258.2 Mn | +28.7% |
| 2032 (forecast) | $6.53 Bn | +$269.3 Mn | +34.3% |
| 2033 (forecast) | $6.81 Bn | +$280.8 Mn | +40% |
| 2034 (forecast) | $7.11 Bn | +$292.9 Mn | +46.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$4.86 Bn
Canada
$1.08 Bn
China
$985.6 Mn
Japan
$711.3 Mn
Germany
$478.5 Mn
France
$339.9 Mn
Brazil
$334.6 Mn
Italy
$312.8 Mn
UK
$276.4 Mn
Spain
$266.9 Mn
Ecuador
$231.4 Mn
India
$233.7 Mn
Saudi Arabia
$217.2 Mn
Mexico
$202.5 Mn
Australia
$166.2 Mn
New Zealand
$135.0 Mn
Russia
$122.7 Mn
South Africa
$100.3 Mn
UAE
$61.4 Mn
Egypt
$39.2 Mn
Philippines
$32.8 Mn
Malaysia
$24.0 Mn
Hong Kong
$22.8 Mn
Thailand
$16.5 Mn
Singapore
$13.8 Mn
Kenya
$8.3 Mn
| Market size, 2025 | $4.86 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $7.11 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 4.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Ingredient, form and distribution channel (see all) |
| Key players | Bayer AG, Haleon PLC, Nature’s Bounty, Nestle, Pharmavite LLC (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026.Source: US Food and Drug Administration. Checked 14 Nov 2026. |
| Active clinical trials | 14 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Joint health supplements contain glucosamine, chondroitin, collagen and other ingredients marketed to ease stiffness and support joints.
Key segments of the joint Health Supplements market include ingredient (Glucosamine, Chondroitin and Collagen) and form (Tablets, Capsules and Powders).
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the joint Health Supplements market. Older adults and their families are spending more on staying active and independent.
Preventive care, personalised plans based on biomarkers and home-based services give the joint Health Supplements market room to grow, especially in fast-ageing countries in Asia and Europe.
Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the joint Health Supplements market.
The joint Health Supplements market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Dietary supplements do not need FDA approval before sale; under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the FDA acts against unsafe or mislabelled products.[2] ClinicalTrials.gov lists 14 studies on Joint Health Supplements that are recruiting, active or about to start in the US.[3] People aged 65 and over: 18.4% of people in 2025, the latest WHO figure for the US.[4]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] US Food and Drug Administration. Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
[4] WHO Global Health Observatory, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
Food and supplement rules, labelling and health-claim regulations govern joint Health Supplements products. Authorities such as the US FDA, EFSA and national food safety bodies set what can be sold and claimed in US.
What doctors and scientists are doing in Joint Health Supplements right now, from free public sources.
14 active trials in the US
Recruiting, about to start, or running now.
18.4 % of people
People aged 65 and over, US, 2025 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
US · 4 shared keywords
US · 3 shared keywords
US · 3 shared keywords
US · 3 shared keywords
US · 3 shared keywords
US · 3 shared keywords
Digital Health · US
Medical Devices · US
Healthcare Services · US
Digital Health · US
Pharmaceuticals · US
Medical Devices · US